Newly reported from the USA: HYPORT Noninferior for GU, GI Toxicity in Prostate Cancer

For patients with prostate cancer, hypofractionated postprostatectomy radiotherapy (HYPORT) is noninferior to conventionally fractionated postprostatectomy radiotherapy (COPORT) in terms of gastrointestinal (GI) or genitourinary (GU) toxicity at two years, according to a study published online March 14 in JAMA Oncology.

Mark K. Buyyounouski, M.D., from Stanford University School of Medicine in California, and colleagues randomly assigned 296 patients with prostate cancer to receive 62.5 Gy in 25 fractions (HYPORT; 144 patients) or 66.6 Gy in 37 fractions (COPORT; 152 patients).

Source: Advances and More licensed by HealthDay

https://advancesandmore.com/advances_article.htm?id=NTNlY2VhNTEtYTQ5OC00YTIyLWI5ZWQtYzRkMDk5YjEwMmFm&client=Nw%3D%3D&section=undefined